Detalhe da pesquisa
1.
Acalabrutinib, venetoclax and obinutuzumab in relapsed CLL: Final efficacy and ctDNA analysis of the CLL2-BAAG trial.
Blood;
2024 Apr 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38620072
2.
Fludarabine, cyclophosphamide, and rituximab as first-line treatment in patients with chronic lymphocytic leukemia: A long-term analysis of the German CLL Study Group (GCLLSG) registry.
Eur J Haematol;
2024 May 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38693677
3.
Chronic Lymphocytic Leukemia: Time-Limited Therapy in the First-Line Setting and Role of Minimal Residual Disease.
Curr Oncol Rep;
26(2): 136-146, 2024 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38175465
4.
Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial.
Nat Med;
30(1): 240-248, 2024 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38071379